Literature DB >> 17397005

Risk of cervical intraepithelial neoplasia grade 2 or 3 after loop electrosurgical excision procedure associated with human papillomavirus type 16 variants.

Long Fu Xi1, Nancy B Kiviat, Cosette M Wheeler, Aimee Kreimer, Jesse Ho, Laura A Koutsky.   

Abstract

Identification of factors associated with risk of relapse after treatment for high-grade cervical intraepithelial neoplasia (CIN) has important clinical implications. Study subjects were women participating in the Atypical Squamous Cells of Undetermined Significance and Low-Grade Squamous Intraepithelial Lesion Triage Study who were treated for CIN3 by loop electrosurgical excision procedure (LEEP) and who had a baseline infection with human papillomavirus type 16 (HPV16). These women were followed every 6 months for 2 years. Post-LEEP CIN2-3 was found in 20 (10.0%) of the 201 women. An adjusted relative risk of 3.1 (95% confidence interval, 1.1-8.9) was associated with HPV16 non-European, compared with European, variants, a finding that is consistent with the variant-related risk of prevalent/incident high-grade CIN.

Entities:  

Mesh:

Year:  2007        PMID: 17397005     DOI: 10.1086/513441

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  8 in total

1.  Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy.

Authors:  Matthew P Morrow; Kimberly A Kraynyak; Cornelia L Trimble; Mark L Bagarazzi; Albert J Sylvester; Michael Dallas; Dawson Knoblock; Jean D Boyer; Jian Yan; Russell Vang; Amir S Khan; Laurent Humeau; Niranjan Y Sardesai; J Joseph Kim; Stanley Plotkin; David B Weiner
Journal:  Clin Cancer Res       Date:  2017-10-30       Impact factor: 12.531

2.  Sequence imputation of HPV16 genomes for genetic association studies.

Authors:  Benjamin Smith; Zigui Chen; Laura Reimers; Koenraad van Doorslaer; Mark Schiffman; Rob Desalle; Rolando Herrero; Kai Yu; Sholom Wacholder; Tao Wang; Robert D Burk
Journal:  PLoS One       Date:  2011-06-23       Impact factor: 3.240

Review 3.  HPV-Testing in Follow-up of Patients Treated for CIN2+ Lesions.

Authors:  Luciano Mariani; Maria Teresa Sandri; Mario Preti; Massimo Origoni; Silvano Costa; Paolo Cristoforoni; Fabio Bottari; Mario Sideri
Journal:  J Cancer       Date:  2016-01-01       Impact factor: 4.207

4.  Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100.

Authors:  Matthew P Morrow; Kimberly A Kraynyak; Albert J Sylvester; Xuefei Shen; Dinah Amante; Lindsay Sakata; Lamar Parker; Jian Yan; Jean Boyer; Christian Roh; Laurent Humeau; Amir S Khan; Kate Broderick; Kathleen Marcozzi-Pierce; Mary Giffear; Jessica Lee; Cornelia L Trimble; J Joseph Kim; Niranjan Y Sardesai; David B Weiner; Mark L Bagarazzi
Journal:  Mol Ther Oncolytics       Date:  2016-11-30       Impact factor: 7.200

5.  Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer.

Authors:  James H A Clubb; Tatiana V Kudling; Camilla Heiniö; Saru Basnet; Santeri Pakola; Víctor Cervera Carrascón; João Manuel Santos; Dafne C A Quixabeira; Riikka Havunen; Suvi Sorsa; Vincent Zheng; Tuula Salo; Leif Bäck; Katri Aro; Sanni Tulokas; Venla Loimu; Akseli Hemminki
Journal:  Front Immunol       Date:  2022-03-07       Impact factor: 7.561

6.  Predictors of persistent cytologic abnormalities after treatment of cervical intraepithelial neoplasia in Soweto, South Africa: a cohort study in a HIV high prevalence population.

Authors:  Yasmin Adam; Cyril J van Gelderen; Guy de Bruyn; James A McIntyre; Diane A Turton; Neil A Martinson
Journal:  BMC Cancer       Date:  2008-07-25       Impact factor: 4.430

7.  Natural Antibodies to Human Papillomavirus 16 and Recurrence of Vulvar High-Grade Intraepithelial Neoplasia (VIN3).

Authors:  Margaret M Madeleine; Lisa G Johnson; David R Doody; Elaine R Tipton; Joseph J Carter; Denise A Galloway
Journal:  J Low Genit Tract Dis       Date:  2016-07       Impact factor: 1.925

8.  Safety and immunogenicity of VGX-3100 formulations in a healthy young adult population.

Authors:  Rebecca K Hollenberg; Diane R Krieger; Robert Samuels; Kim Kraynyak; Albert Sylvester; Matthew Morrow; Jean Boyer; Michael Dallas; Prakash K Bhuyan
Journal:  Hum Vaccin Immunother       Date:  2019-12-20       Impact factor: 3.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.